anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity has been linked to prostate cancer in a stage-dependent manner, having no association with cancer initiation but correlating with disease progression in men with prostate cancer. Given the rising obesity rate and its association to aggressive prostate cancer, there is a growing need to understand the mechanisms underlying this relationship to identify patients at increased risk of lethal disease and inform therapeutic approaches. In this issue of Cancer Research, Boufaied and colleagues describe how diets high in saturated fatty acids promote MYC-driven prostate cancer. Leveraging MYC-expressing genetically engineered and allograft mouse models fed either a control low-fat or high-fat diet (HFD) enriched in saturated fatty acids, the authors found using digital pathology that HFD-fed mice exhibited increased tumor invasion. Metabolomics, transcriptomics, immunoblotting, and positron emission tomography of tumors from these mice demonstrated that a HFD promoted a metabolic shift in the tumors towards glycolysis. These preclinical data were supported by findings from two large clinical cohorts revealing that men diagnosed with prostate cancer and who consumed high levels of saturated fatty acids possessed tumors bearing glycolytic signatures. Deconvolution analyses and immunohistochemistry validation showed that these tumors also displayed increased angiogenesis and infiltration of immunosuppressive macrophages and regulatory T cells, the latter of which was also correlated with high saturated fat intake-associated glycolytic signatures in patient tumors. Together, these findings suggest that diets rich in saturated fatty acids, rather than obesity alone, accelerate MYC-driven prostate cancers through shifting tumor metabolism and shaping the tumor microenvironment. See related article by Boufaied et al., p. 1834.
A care reminder system includes an electrical pattern measurement, an electrical characteristics database, an electricity consumption analysis unit, a behavior detection unit, a behavior pattern database, a behavior pattern analysis unit and an early warning unit. The electrical pattern measurement unit measures the electrical characteristics of electrical appliances. The electrical characteristics database stores electricity characteristics and normal electricity usage rules. The electricity consumption analysis unit compares the electricity consumption characteristics with the normal electricity consumption rules, and generates a signal for the deviation of the electricity consumption characteristics when the electricity consumption characteristics deviate from the normal electricity consumption rules by a predetermined range. The behavior detection unit detects the behavior state of the user. The behavior pattern database stores behavior states and normal behavior patterns. The behavior pattern analysis unit compares the behavior state with the normal behavior pattern, and generates a behavior state deviation signal when the behavior state deviates from the normal behavior pattern to a predetermined degree. The early warning unit generates an early warning reminder when it receives a signal of deviation of power consumption characteristics and a signal of deviation of behavior state within a predetermined period.
This will be a pre-post experimental design study. The pre-intervention group of 80 hip or knee replacement surgery patients will receive the Amsterdam Preoperative Anxiety and Information Scale (APAIS) and Pittsburgh Sleep Quality Index (PSQI) in Preop Holding prior to having their block for their surgery. The block resident will give and collect the scale and inventory to patients. Patients are given these surveys as part of a quality improvement initiative, independently of this study. The survey data will be entered into the secure electronic research database. Following this, the post-intervention group of 80 patients will be given copies of previous patients' stories at their last visit to the surgeon's office prior to their surgery. These stories will be administered to all hip and knee surgery patients as part of the new standard of care due to a perioperative QI initiative, independently of this study taking place. These subjects will also receive the APAIS and PSQI for assessment in Preop Holding prior to their block for surgery, as part of the new standard of care. A third party broker will then de-identify the survey data and provide it to the research team for analysis. A two-sided independent t-test will be performed to evaluate the differences in anxiety and sleep scores between the pre- and post-intervention groups.
The JessieHug device will be placed on infants two times a week to determine usability, tolerability and safety. Clinical accuracy will be assessed in one inpatient (newborn cohort) or outpatient (2 month and 4 month cohorts) session.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes the use of β-diethylaminopropionic acid ortho-bromoanilide hydrochloride as an anti-inflammatory and antibacterial agent. Invention proposes an ointment based on this agent. The preparation inhibits the foot edema, shows an bacteriostatic effect with respect to some microorganisms. EFFECT: enhanced pharmacological effect of an agent. 2 cl, 8 tbl, 3 ex
Participants will be administered QL1101 7.5 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Fluzoparib will be administered orally twice daily continuously throughout each 21-day cycle. On Day 1 of each cycle, fluzoparib will be administered upon completion of QL1101 infusion. The starting dose of fluzoparib will be based on the participant's Baseline actual body weight or platelet count.
An anti-cancer combination containing a phosphoinositide3-kinase inhibitor (PI3Ki) and/or a topoisomerase inhibitor is a sustained-release injection, which contains a sustained-release microsphere and a menstruum. The sustained-release microsphere contains PI3Ki and/or topoisomerase inhibitor and sustained-release auxiliary materials; the menstruum is an ordinary menstruum or a special menstruum containing a suspending agent. The viscosity of the suspending agent is 100cp to 3000cp (at the temperature of 20 DEG to 30 DEG) and the suspending agent is selected from carboxymethylcellulose sodium, etc. The sustained-release auxiliary materials are selected from a polyphosphonate copolymer of p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP/TC), p(BHET-EOP/TC ), p(BHDPT-EOP/TC), p(BHDPT-EOP/TC), p(CHDM-HOP) or p(CHDM-EOP), and the like, or a copolymer of polyphosphate ester and polylactic acid, polifeprosan, dienoic fatty acid or decanedioic acid, a copolymer or a mixture of p(erucic acid dimer-decanedioic acid) or a copolymer or a mixture of p(boletic acid-decanedioic acid). The anti-cancer combination is also made into a sustained-release implanting agent, which can be injected or placed in or around tumor to maintain the effective medicine density for more than 40 days. The anti-cancer combination can also obviously reduce the general reaction of the medicine and selectively enhance the curing effect of non-operational therapies such as radiotherapy and chemotherapy.
PROBLEM TO BE SOLVED: To provide an antiserum for a protein which manifests itself at increased rate in carcinogenesis by fabricating an antiserum for a protein composed of amino acids described at a specific number on a sequence chart. SOLUTION: Liver is extracted from a liver-cancer rat for RNA preparation, and using subtraction method a gene-library solution is prepared from the RNAs obtained. Each of the genes is inserted into a vector and introduced into coliform bacilli, which are cultured to form colonies. Of them, a white colony is selected as screening seed bacilli, and genes are extracted therefrom using alkali method. From the genes extracted, that which manifests itself at increased rate in case of liver cancer is isolated, and its base sequence is determined. Further, the amino acid sequence of the protein which that gene codes for is also determined and described at a sequence number 1 on a sequence chart. Then an antiserum for the protein of the amino acid sequence is fabricated, whereby the antiserum for the protein that manifests itself at increased rate in carcinogenesis can be obtained.
Modern intrauterine devices are highly effective long acting reversible forms of contraception. The Mirena IUD is 99.8% effective and the Paragard copper IUD is 99.2% effective in preventing pregnancy (Zieman 2010). Fear of intrauterine device placement can be a barrier to obtaining this highly effective form of birth control. The current standard of care for pain management during and after IUD placement is no medication, as randomized control trials published to date have limited data regarding use of medications to decrease pain. There has been one trial to suggest that the use of naproxen with 1% lidocaine paracervical block compared to paracervical block alone may decrease pain after IUD placement in primarily nulliparous patients. However, this study was with the much wider and no longer available Dalkon Shield IUD. In addition, this study did not show any significant decrease in pain scores during IUD placement (Massey 1974). Studies to evaluate effectiveness of motrin and misoprostol have shown no significant decrease in pain scores during and after IUD insertion, although the majority of participants in these studies were multiparous (Jensen 1998, Hubacher 2006, Saav 1997). There is some suggestion that 2% lidocaine gel one minute prior to IUD insertion may have some decrease in pain, although this study was poorly designed (Oloto 1996).

There have been no studies published to date regarding the use of ketorolac for decreasing pain during and after IUD placement. Ketorolac is an acetic acid NSAID that reversibly inhibits COX 1 and 2, leading to decreased formation of prostaglandin precursors, and is indicated for the use of moderate acute pain in the short term setting. Its administration in the office setting may be good option for providers since intramuscular administration leads to analgesia beginning at 30 minutes, maximal effect 1 to 2 hours after administration, and duration of analgesia approximately 4 to 6 hours for the 30mg intramuscular injection.

Although there is no standard of care in regards to pain medication administration prior to IUD placement, providers at UCSD often suggest certain options. These include ibuprofen at least one hour prior to the procedure, or ibuprofen taken within a few hours after the procedure, or ketorolac injection at least 15-30 minutes prior to the procedure. It would be beneficial for providers to have an evidence based option for patients.
Patients will undergo bilateral RFA; the right side will be done following the traditional approach, and the left side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.
PURPOSE: A cosmetic composition including N-acetyl-L-glutamine is provided to prevent skin aging and improve wrinkles by eliminating oxidizing substances, biosynthesizing collagen, promoting cell proliferation and keratin hydration. CONSTITUTION: A cosmetic composition including N-acetyl-L-glutamine contains N-acetyl -L- glutamine as active ingredients. 0.1-15 weight% of the N-acetyl-L-glutamine is included based on the total cosmetic composition. The cosmetic composition additionally includes an emulsifier. The emulsifier is monooleic acid ester or glycerol monostearin acid ester. The cosmetic composition having oxidizing substances elimination effects includes the N-acetyl -L- glutamine as active ingredient. The cosmetic composition having collagen biosynthesis effects includes the N-acetyl -L- glutamine as active ingredient. A cosmetic composition having cell proliferation promotion effects includes the N-acetyl -L- glutamine as active ingredient. The cosmetic composition having the keratin hydration acceleration effect includes the N-acetyl -L- glutamine as active ingredient.
Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
FIELD: medicine, pharmacy. SUBSTANCE: method involves hydrolysis of glycyrrhizic acid in an aqueous medium in the presence of sulfocationite in H-form at ratio parent product : sulfocationite = 1:75. Hydrolysis is carried out at 98-100 C for 9 h, not less. Then sulfocationite is separated, the obtained hydrolyzate is condensed to 1/5-1/10 of initial volume, ethanol is added up to concentration 40-50% in mixture. Mixture is settled for 24 h, precipitate is filtered off, dissolved in 1.5-2 volumes of 95% ethanol at heating, hot water is added up to alcohol concentration 40-50% in mixture and settled again for 24 h for glycyrrhetic acid crystrallization. Precipitate is filtered off, washed off with water on filter and dried at 100-105 C. EFFECT: increased yield, simplified technological process, improved ecology.
Subjects will receive either a 20min 10hz TMS treatment, or a 3min theta-burst TMS treatment at certain monthly intervals. The TMS treatment protocol they receive depends on what they received in their acute clinical treatment. Subjects in the arm will be tapered off antidepressant medication before TMS treatment begins. Subjects will be assessed monthly for depression using QIDS and PHQ9.
PURPOSE:To industrially obtain high-purity ecdysone in good yield according to simple operation. CONSTITUTION:Ecdysone in a plant is extracted with water or a hydrous hydrophilic solvent and the resultant extract solution is regulated to alkaline conditions to suppress formation of precipitates. The obtained alkaline extract solution is then treated by a reverse phase-based adsorbent to wash the reverse phase-based adsorbent with an alkaline washing agent. Thereby, impurities are removed. Ingredients adsorbed on the aforementioned reverse phase-based adsorbent are subsequently extracted with a solvent to crystallize the ecdysone from the eluate. As a result, the high-purity ecdysone is obtained.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of filgrastim or of other filgrastim products. 

While available data suggest that a small proportion of patients developed binding antibodies to filgrastim products, the nature and specificity of these antibodies has not been adequately studied. In clinical studies using filgrastim, the incidence of antibodies binding to filgrastim was 3% (11/333). In these 11 patients, no evidence of a neutralizing response was observed using a cell based bioassay. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of filgrastim products is unknown.

Cytopenias resulting from an antibody response to exogenous growth factors have been reported on rare occasions in patients treated with other recombinant growth factors.
• More recently, the so-called lung-protective intraoperative ventilation strategies have been advocated to prevent lung injury. Such strategies aim at minimizing lung hyperinflation as well as cycling collapse and reopening of lung units, through the use of low tidal volumes (VTs) and positive end-expiratory pressure (PEEP). However, despite huge improvements in surgical and anesthesia techniques and management. It is surprising that, so far, mortality and pulmonary complication rates were not reduced over time .Recently, several investigations suggest an association between high driving pressure (the difference between the plateau pressure and the level of PEEP) and outcome for patients with acute respiratory distress syndrome. It is uncertain whether a similar association exists for high driving pressure during surgery and the occurrence of postoperative pulmonary complications. In this issue, Ary S Neto and colleagues report an individual patient data meta-analysis further investigating the risk of mechanical ventilation in healthy individuals during general anesthesia .After both a multivariate and mediation analysis, the driving pressure, but not the tidal volume or the positive end-expiratory pressure applied, seemed to be the only parameter that was associated with the development of postoperative pulmonary complications. This randomized controlled trial is aims to prove that driving pressure limited ventilation is superior in preventing postoperative pulmonary complications to existing protective ventilation.
The present invention relates to nanometer toothpaste. The prior nanometer toothpaste has high cost and large undulation of a sterilization effect. A technical problem for the present invention to solve is how to conquer the above disadvantages of the prior nanometer toothpaste to provide nanometer toothpaste, which is provided with low cost, stable sterilization effect and can be used for curing dental diseases. In order to solve the above technical problem, the nanometer toothpaste of the present invention contains a nanometer grade TiO<SUB>2</SUB>, an adhesive, a vesicant, a wetting agent and water, wherein the nanometer grade TiO<SUB>2</SUB> takes 3 to 17 percent of the total weight. The special character of the present invention lies in that the present invention also includes a nanometer silver-loaded bactericide which takes 1 to 50 percent of the total weight. After adopting the above technical proposal, the nanometer toothpaste of the present invention has the advantages of the low cost, stable sterilization effect and being able to be used for preventing decayed tooth and is an ideal regenerate product of the prior medical toothpaste.
Myocardial ischemia is a key determinant of clinical prognosis in patients with coronary artery disease. In this regard, functional assessment of intermediate coronary stenoses with transtenotic pressure ratios provides a more accurate measure of stenosis-derived myocardial ischemia in comparison to conventional coronary angiography (3-5). One of the major clinical benefit of fractional flow reserve (FFR) is that, by acting as a gatekeeper, non-ischemia-causing lesions suitable for optimal medical treatment can be accurately identified, avoiding unnecessary coronary stenting. However, despite being support with the highest level of recommendation by the current guidelines for guiding clinical-decision making, adoption of FFR in the real world practice is still very low, mainly due to the need of hyperemic agents like adenosine that frequently cause patient discomfort, and time consumption. To overcome such limitations of pressure-wire derived index from the need of adenosine, other alternatives have been looking for over the last years. Instantaneous wave-free ratio (iFR), a resting trans-stenotic pressure index obtained as the ratio of distal coronary pressure to aortic pressure during the diastolic wave-free period, demonstrated a good diagnostic accuracy to define functional significance of coronary lesions without need of adenosine, using FFR as reference. Recently, two large, randomized trials demonstrated that iFR-guided coronary revascularization is clinically non-inferior to FFR-guided revascularization with respect to one-year risk of major adverse cardiac events. Accordingly, like FFR, iFR is now receiving the highest level of recommendations to guide clinical decision making in patients with stable intermediate coronary stenosis. A new adenosine-free index, the resting full-cycle ratio (RFR), has recently emerged. RFR is defined as the lowest ratio of intracoronary distal pressure to aortic pressure under resting condition, irrespective of systole or diastole, and has demonstrated equivalent diagnostic performance to iFR. RFR has an advantage over iFR, because it is not limited by sensitive land marking of components of the pressure waveform unlike iFR.

This novel physiologic index without the need of adenosine has the potential to increase the worldwide adoption of coronary physiology in guiding coronary revascularization in daily clinical practice. However, there is a paucity of important data regarding clinical outcomes of RFR-guided revascularization strategy. We hypothesize long-term clinical outcome of RFR-guided revascularization is non-inferior to that of FFR-guided revascularization, and it reduce the rate of PCI than FFR-guided revascularization. Therefore, we sought to investigate the long-term effectiveness and safety of RFR-based decision making in patients with one or more intermediate coronary stenosis, and to assess whether it is non-inferior to FFR-guided revascularization.
A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
BACKGROUND: The olfactory cleft (OC) is the most important anatomical site for the maintenance of olfactory function. Obstruction of airflow in the OC by various conditions, such as inflammation, leads to poor olfactory function. Therefore, it is important to increase OC airflow while performing endoscopic sinus surgery (ESS). However, no technique to increase airflow has yet been established.
METHODS: We designed a superior turbinate lateralization (STL) procedure that displaces the entire ST bone laterally by eliminating the connection between the posterior ST and the anterior wall of the sphenoid sinus. The effect of the STL procedure was investigated in terms of anatomy and olfactory function.
RESULTS: ESS with the STL procedure was performed on seven patients with chronic rhinosinusitis and nasal polyps. The cross-sectional area of the OC at 3 months postoperatively was significantly larger than that before ESS. In addition, the Open Essence test and questionnaires revealed significantly improvements in sense of smell. Airflow in the OC was significantly higher in STL procedure group than in the non-STL procedure group.
CONCLUSION: The STL procedure enlarges the bony framework of the OC, and by increasing OC airflow, facilitates the transport of odorants to the olfactory epithelium, thereby improving olfactory perception.